For U.S. Healthcare Professionals Only
Register for Samples

Education and support resources for you and your patients taking Toujeo®

Request samples of Toujeo pens*

Request samples

*US licensed prescribers are required to register to request samples.

Select a resource below to view, download, or print

Expand All | Collapse All

Review Toujeo pivotal trials and clinical publications online

Use the links below to read the study abstracts and full external publications.

BRIGHT

The first head-to-head, randomized controlled clinical trial of Toujeo vs Tresiba®.

Read more

BAILEY

A PK/PD study evaluating the within-day variability of Toujeo and Tresiba in patients with T1DM.

Read more

EDITION 3

Insulin-naive patients with type 2 diabetes mellitus on oral glucose-lowering drugs.

Read more

EDITION 2

Patients with type 2 diabetes mellitus using oral antidiabetic agents and basal insulin.

Read more

EDITION 1

Patients with type 2 diabetes mellitus using basal and mealtime insulin.

Read more

EDITION 4

Patients with type 1 diabetes mellitus.

Read more

Clamp Study I

Evaluated the steady-state PK/PD profile of Toujeo.

Read more

Clamp Study II

Evaluated the day-to-day and intraday variability of Toujeo.

Read more

Toujeo has been studied versus Lantus® (insulin glargine injection) 100 Units/mL in four pivotal clinical trials (the EDITION study program) involving more than 3000 patients and in two euglycemic clamp studies to assess pharmacokinetics (PK) and pharmacodynamics (PD).

All studies in the EDITION clinical program were 26-week, open-label, controlled, titrate-to-target, noninferiority studies in adults with diabetes not at A1C goal (range: 7%-10% or 11%), randomized to Toujeo or Lantus once daily. All patients were titrated to an FPG goal of 80-100 mg/dL (T2DM) or 80-130 mg/dL (T1DM).

Toujeo Dosing Guide

Information on the initiation and titration of Toujeo

English

Toujeo SoloStar® Instructions for Use

Instructions for using the Toujeo SoloStar pen

English

Toujeo® Max SoloStar® Instructions for Use

Instructions for using the Toujeo Max SoloStar pen

English

Toujeo Titration Worksheet

Completed by a healthcare professional, this form provides dosing instructions to patients

English

Blood Sugar Log

Form for tracking blood glucose values through the week

EnglishSpanish

Meal Planning and Exercise Tips

Tips for keeping active to stay healthy

EnglishSpanish

How to Prepare for and Inject Toujeo

Instructions for using the Toujeo pens

English

Hypoglycemia Safety

Tips for patients about understanding hypoglycemia

EnglishSpanish

Learn about the Toujeo Max SoloStar Pen Features

Key features of the Max SoloStar pen

English

Toujeo Max SoloStar Pharmacy FAQs

FAQs about the Max SoloStar pen

English

Insulin, Glucose and You

Insulin and Glucose

When you hear the word insulin, you may think of a drug taken by people who have diabetes.

While this is true, what you may not know is that insulin is one of the many hormones created in the human body.

Insulin is important to the body. It allows blood sugar (or glucose) to get into cells to provide them with energy.

When you eat, your body breaks down food into glucose in your small intestine.

This is your body’s source of energy for everything it does, from working and thinking to exercising and healing.

Glucose travels through your bloodstream, looking for individual cells that need energy.

For glucose to get into the cells, it requires insulin.

Insulin is the key that unlocks cells for glucose to enter and deliver energy.

When insulin arrives, it signals the cell to activate glucose transporters.

These transporters pull glucose through cell walls.

When glucose moves into the cell, it delivers energy.

Insulin Deficiency

Insulin is normally produced in the pancreas by specialized cells called beta cells.

When glucose enters your bloodstream, the pancreas matches it with the right amount of insulin to move glucose into your cells.

In people with diabetes, this process doesn't work as it should. In type 1 diabetes, scientists believe the body's immune system mistakenly attacks and destroys beta cells in the pancreas. A person with type 1 diabetes loses the ability to produce insulin.

In type 2 diabetes, the pancreas is not producing enough insulin to meet the body's needs. Over time, the amount of insulin typically becomes less and less.

Insulin Resistance

In some type 2 diabetes patients, cells build up a resistance to insulin. Even though there may be insulin in the bloodstream, it is not enough to unlock cells to allow glucose to enter.

As a result, it takes more insulin to find the right key to unlock the cell for glucose. This makes it more difficult for cells to get the energy they need.

The Effects of Diabetes

When glucose can't get into cells—either because there isn't enough insulin or because the body is resisting it—glucose begins to build up in the bloodstream.

As a result, all that energy is wasted. It does not get to cells where it is needed. Without glucose in your cells, they lack the energy they require to keep your body working.

ANNOUNCER: These instructions do not replace the guidance of your doctor or the instructions for use that accompanies the Toujeo (insulin glargine injection) 300 Units/mL SoloStar or Toujeo Max SoloStar pens. People who have vision problems should not use the Toujeo SoloStar or Toujeo Max SoloStar pen without help from a person trained to use the respective pens.

MAX AMY: In this diabetes journey we’re on, have you ever wished you could go back in time and tell yourself the things that you know now, but you didn’t know then?

MAX AMY: Thanks to the wonders of modern technology, we can.

MAX AMY: Hey look at that, our first SoloStar pen! I remember that.

MAX AMY: It was a really big deal when I came home with my first pen – it feels like it was only yesterday.

PAST AMY: Oh hey, is that one the same as this one?

MAX AMY: Well your pen is the SoloStar. This one is the Max SoloStar. They’re very similar but there’re some really important differences – but I’ll get to those in a second.

MAX AMY: Did your doctor show you how to use it?

PAST AMY: Yeah, she showed me, but now that I’m home I still have some questions.

MAX AMY: Let me help you get the hang of this.

MAX AMY: There are six steps you need to know: Check the pen, attach the needle, test for safety, select the dosage, inject the insulin, and then remove the needle.

PAST AMY [repeating as if memorizing]: OK. Check the pen, attach the needle, test for safety, select the dosage, inject the insulin, and remove the needle.

MAX AMY: That’s it! You’re ahead of the game already! I knew there was a reason why I liked you. 

MAX AMY: So, before we do anything, we’re going to make sure the pen is at room temperature, that we have the correct pen, and that it’s working properly.

MAX AMY: Did you take the pen out of the refrigerator about an hour ago? 'Cause cold insulin can be painful…

PAST AMY: Really? Who knew?

MAX AMY: You.

PAST AMY: Good point. This one’s been out of the fridge about an hour.  

MAX AMY: Now look at your pen. I mean, really look at it.

MAX AMY: Is that your pen?

PAST AMY: Yeah.

MAX AMY: Great. Take off the pen cap and check the insulin. It’s clear, not cloudy?

PAST AMY: Clear.

MAX AMY: Perfect! If the insulin’s cloudy, don’t use it, just take it back to your pharmacy.

MAX AMY: Is it past the use-by date?

PAST AMY: Nope.

MAX AMY: Great! Now it’s time to attach the needle.

MAX AMY: Remember, you’re going to need a fresh needle every time you use the pen.

MAX AMY: Don’t reuse and never share needles.

PAST AMY: Even with you?

MAX AMY: Yes, even with me.

PAST AMY: What kind of needles can I use?

MAX AMY: These Kind.

MAX AMY: Before you attach the needle, sterilize the tip of the pen with an alcohol wipe.

MAX AMY: Then with the needle you’re going to peel off the protective seal and screw the needle onto the pen until it feels fixed.

MAX AMY: Then you’re going to remove the outer cap and put that somewhere safe. Then remove the inner needle cap and throw it in the trash.

PAST AMY: Keep the outer cap, toss the inner, got it.

MAX AMY: That’s step two done! With me so far?

PAST AMY: I’m with you.

MAX AMY: Yes, you are. So, before we do anything else, we need to make sure the pen’s working properly.

PAST AMY: What could go wrong?

MAX AMY: Well, sometimes the insulin won’t come out, so we usually check for that.

PAST AMY: OK.

MAX AMY: Testing the pen also resets the dosage knob which is also important.

PAST AMY: Great, so how do I do that?

MAX AMY: Turn the dosage dial to 3, then you’re going to hold it straight up and you’re going to press the injection button all the way in.

MAX AMY: If you see insulin coming out of the needle, then the pen is working and you’re good to go.

MAX AMY: However, if you don’t see insulin coming out, repeat that last step again.

MAX AMY: If you have a new pen, you may need to do this up to six times. Just to get that working. If it still doesn’t work, you need to replace the needle.

PAST AMY: Like in step two?

MAX AMY: Precisely. Oh, and by the way, if you see bubbles in your insulin, don’t sweat it.

PAST AMY: Aren’t bubbles in injections bad?

MAX AMY: Nope, not here. You’ve been watching too much TV.

MAX AMY: Ready to inject some insulin?

PAST AMY: OK.

MAX AMY: First, we need to select the correct dosage. So, we’re going to turn the dosage selector to your dose.

MAX AMY: Whatever you and your doctor discussed is what you turn the dial to.

PAST AMY: OK, I need 38 units, so I turn the dial to 38, correct?

MAX AMY: Correct.

MAX AMY: Now this is important: If you have the SoloStar pen, the increments on the dial are one click for one unit, but on the Max SoloStar pen, it’s one click for two units.

MAX AMY: So, don’t dial your dose by counting the clicks, or you may dial the wrong dose.

MAX AMY: Either way, just turn the dial so your prescribed dose appears in this window. If there’s not enough insulin in the pen for your prescribed dose, you’ll only be able to dial to the amount that’s left in the pen, and then you’ll need to supplement with a new pen.

PAST AMY: How do I know whether I need the SoloStar or the Max SoloStar?

MAX AMY: As your diabetes changes, your dose may change too, so your doctor may recommend you use a Max SoloStar. Like me.

PAST AMY: That makes total sense.

MAX AMY: OK, we’re in the home stretch.

MAX AMY: Are you ready for your injection?

PAST AMY: Where can I inject?

MAX AMY: You can inject your dose here, here or here.

MAX AMY: Push the needle into your skin, but don’t touch the injection button yet.

MAX AMY: Put your thumb on the button, press all the way in and hold.

MAX AMY: Hold the button in. When you see “0” in the window, then count to five to make sure you get your full dose.

MAX AMY: After counting to five, release the button and remove the needle from your skin.

PAST AMY: OK, that was pretty easy.

PAST AMY: Well, I barely noticed it at all. How do they do that?

MAX AMY: Thin needles.

MAX AMY: We’re almost done. Now we just need to remove the needle and throw it away safely.

PAST AMY: This really is pretty straightforward.

MAX AMY: I know, right?

MAX AMY: To remove the needle, get the outer needle cap we set aside earlier and carefully place it back on the pen. You put that somewhere safe, right?

PAST AMY: Yep.

MAX AMY: OK.

MAX AMY: These things are sharp. Avoid puncturing the cap, 'cause it will go through.

MAX AMY: Grip and squeeze the widest part of the outer needle cap, then turn your pen several times with your other hand to remove the needle.

PAST AMY: But what if it doesn’t come off right away?

MAX AMY: Just keep trying, it’ll come off eventually.

MAX AMY: Once the needle’s been removed, then we dispose of it in a puncture resistant container.

PAST AMY: Can I just leave the needle on and use it again later?

MAX AMY: No, that’s not a great idea for several reasons: It can leak or get clogged if you leave it on, air could get into the insulin, and there’s the possibility of a bacterial infection.

PAST AMY: So, do I need to put the pen back in the refrigerator when I’m done?

MAX AMY: Nope, that’s the great thing about these pens – you’re good for up to eight weeks after your first use without refrigeration.

PAST AMY: Well that’s handy.

MAX AMY: It sure is.

MAX AMY: So, there you go. That’s all six steps of how to use the Toujeo SoloStar and Max SoloStar insulin pens.

MAX AMY: Just to recap, we learned how to check the pen, attach the needle, test for safety, select your dosage, inject the insulin, and then remove the needle.

PAST AMY: Hey, that was really straightforward. I know the doctor explained it to me, but it really helped to have you explain it again.

MAX AMY: No sweat.

PAST AMY: You know, now that I know, it’s pretty simple. If I wasn’t so nervous, I guess I could have taught myself to do it.

MAX AMY: Well, you know, you kinda did.

ANNOUNCER: An unopened Toujeo SoloStar or Toujeo Max SoloStar pen should be stored in the refrigerator with the pen cap on, at a temperature between 36 degrees Fahrenheit and 46 degrees Fahrenheit (2 degrees Celsius and 8 degrees Celsius) in the box it came in.

Do not freeze new pens.

Refrigerate pens until expiration date.

Discard pens after the expiration date.

An opened Toujeo SoloStar or Toujeo Max SoloStar pen should be stored at room temperature below 86 degrees Fahrenheit (30 degrees Celsius).

Do not refrigerate an opened pen.

Keep out of direct heat and light.

Do not store your pen with the needle attached.

Store your pen with the pen cap on.

Keep pens and needles out of the reach of children.

Discard 56 days after first use, even if the pen still contains insulin.

What is Toujeo® (insulin glargine injection) 300 Units/mL?
Prescription Toujeo is a long-acting man-made insulin used to control high blood sugar in adults and children who are 6 years of age and older with diabetes mellitus.

Toujeo is not for use to treat diabetic ketoacidosis

It is not known if Toujeo is safe and effective in children under 6 years of age.

Important Safety Information 

Do not take Toujeo if you have low blood sugar or if you are allergic to insulin or any of the ingredients in Toujeo.

Do not share your pen(s) with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.

Before starting Toujeo, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant, or if you are breastfeeding or planning to breastfeed. 

Change (rotate) your injection sites within the area you chose with each dose to reduce your risk of getting lipodystrophy (pitted or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. Do not use the same spot for each injection or inject where the skin is pitted, thickened, lumpy, tender, bruised, scaly, hard, scarred or damaged. 

Heart failure can occur if you are taking insulin together with pills called TZDs (thiazolidinediones), even if you have never had heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with Toujeo. Your treatment with TZDs and Toujeo may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have any new or worsening symptoms including:

Shortness of breath

Sudden weight gain

Swelling of your ankles or feet

Tell your doctor about all the medications you take, including OTC medicines, vitamins, and supplements, and herbal supplements.

Toujeo should be taken at the same time once a day. Test your blood sugar levels daily while using any insulin. Do not change your dose or type of insulin without talking to your doctor. Verify you have the correct insulin before each injection. Do NOT use a syringe to remove Toujeo from your pen. Your dose for Toujeo may be different from other insulins you have taken. Any change of insulin should be made cautiously and only under medical supervision.

Do NOT dilute or mix Toujeo with any other insulin or solution. It will not work as intended and you may lose blood sugar control, which could be serious. Use Toujeo only if the solution is clear and colorless with no particles visible. 

While using Toujeo, do not drive or operate heavy machinery until you know how Toujeo affects you. Don’t drink alcohol or use other medicines that contain alcohol.

The most common side effect of any insulin, including Toujeo, is low blood sugar (hypoglycemia), which may be serious and life-threatening. Severe hypoglycemia may cause harm to your heart or brain. Symptoms of serious low blood sugar may include shaking, sweating, fast heartbeat, and blurred vision.

Toujeo may cause severe allergic reactions that can lead to death. Get medical help right away if you have:

A rash over your whole body

Shortness of breath

Swelling of your face, tongue, or throat

Extreme drowsiness, dizziness, or confusion

Trouble breathing

Fast heartbeat

Sweating

Toujeo may have additional side effects including swelling, weight gain, low potassium, and injection site reactions which may include change in fat tissue, skin thickening, redness, swelling, and itching.

Toujeo® SoloStar® and Toujeo® Max SoloStar® are single-patient-use prefilled insulin pens. It is important to perform a safety test when using a new pen for the first time. Talk to your doctor about proper injection technique and follow instructions in the Instruction Leaflet that comes with the pen.

© 2020 sanofi-aventis U.S. LLC.
All rights reserved.
SAUS.TJO.17.12.9487(2) | 01/20


Back to Video

Video Resources

Demonstration and comparison of our two pens

Prior authorization

Sanofi Patient ConnectionTM can help your office obtain prior authorization for access to Toujeo

Additional professional resources

Find the full list of resources for Toujeo

Toujeo is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus.

Limitations of Use: Toujeo is not recommended for treating diabetic ketoacidosis.

Important Safety Information

Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.

Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus®. The concentration of insulin glargine in Toujeo is 300 units per mL.

Insulin pens and needles must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision. Changes in insulin regimen, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia.

Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.

Unit for unit, patients started on, or changed to, Toujeo required a higher dose than patients controlled with Lantus. When changing from another basal insulin to Toujeo, patients experienced higher average fasting plasma glucose levels in the first few weeks of therapy until titrated to their individualized fasting plasma glucose targets. Higher doses were required in titrate-to-target studies to achieve glucose control similar to Lantus.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Toujeo, and may be life-threatening.

Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection.

Do not dilute or mix Toujeo with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Toujeo via an insulin pump or intravenously because severe hypoglycemia can occur.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Toujeo, monitor and treat if indicated.

A reduction in the Toujeo dose may be required in patients with renal or hepatic impairment.

As with all insulins, Toujeo use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Toujeo include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Toujeo SoloStar® and Toujeo Max SoloStar®

Toujeo SoloStar and Toujeo Max SoloStar are single-patient-use prefilled insulin pens. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose levels. It is especially important to perform a safety test when a patient is using a new pen for the first time.

Do not withdraw Toujeo from the SoloStar and Max SoloStar single-patient-use prefilled pens with a syringe.

All registered trademarks cited are property of their respective owners.

*

*Eligibility Restrictions and Offer Terms:

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. The Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend the program without notice.

  • Pay as low as $0 up to $99 for a 30-day supply, depending on insurance coverage. Valid up to 10 packs per fill; Offer valid for one fill per 30-day supply

Eligibility Restrictions and Offer Terms:

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use the savings card. The Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend the program without notice.

  • Pay as low as $0 up to $99 for a 30-day supply, depending on insurance coverage. Valid up to 10 packs per fill; Offer valid for one fill per 30-day supply.

*Eligibility Restrictions and Offer Terms:

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. The Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend the program without notice.

  • Pay as low as $0 up to $99 for a 30-day supply, depending on insurance coverage. Valid up to 10 packs per fill; Offer valid for one fill per 30-day supply.

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use the savings card. The Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend the program without notice.

  • Pay as low as $0 up to $99 for a 30-day supply, depending on insurance coverage. Valid up to 10 packs per fill; Offer valid for one fill per 30-day supply.

Eligibility Restrictions and Offer Terms:

* Sanofi Copay Program: This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. The Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. Upon registration, patients receive all program details.

  • Pay as low as $0 up to $99 for a 30-day supply, depending on insurance coverage. Valid up to 10 packs per fill; Offer valid for one fill per 30-day supply.

Insulins Valyou Savings Program: Sanofi insulins included in this program are: Admelog® (insulin lispro injection) 100 Units/mL, Toujeo® (insulin glargine injection) 300 Units/mL, Lantus® (insulin glargine injection) 100 Units/mL and Apidra® (insulin glulisine injection) 100 Units/mL.

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs, or commercial/private insurance. Only people without prescription medication insurance can apply for this offer. Void where prohibited by law. For the duration of the program, eligible patients will pay $99 for up to 10 vials or packs of SoloStar pens per fill or up to 5 packs of Max SoloStar pen per fill. Offer valid for one fill per month. To pay $99 per month, you must fill all your Sanofi Insulin prescriptions at the same time, together each month. Not valid for SOLIQUA 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL or Toujeo Max SoloStar pen. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment.  

Savings may vary depending on patients’ out-of-pocket costs. Upon registration, patients receive all program details. Sanofi US reserves the right to rescind, revoke, or amend these programs without notice.

© 2020 sanofi-aventis U.S. LLC. All rights reserved.

Legal Disclaimer | Privacy Policy | Contact SANOFI

This site is intended for use by U.S. Healthcare Professionals only.

MAT-US-2022029-v1.0-11/2020 Last Update: November 2020

Important Safety Information

Important Safety Information

Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.

Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus®. The concentration of insulin glargine in Toujeo is 300 units per mL.

Insulin pens and needles must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens cautiously and only under medical supervision. Changes in insulin